We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Chimeric Hybrid Silkworms Could Improve Surgical Sutures

By HospiMedica International staff writers
Posted on 19 Jan 2012
Transgenically engineered silkworms could spin silk almost as strong as spider silk, which could possibly be used to make sutures, artificial limbs, tendons, tissue scaffolds, and microcapsules.

Researchers at the University of Notre Dame (IN, USA) used piggyBac (PB) vectors to create transgenic silkworms that produced composite silk fibers with chimeric silkworm/spider silk proteins that were integrated in an extremely stable manner. More...
These composite fibers were (on average), tougher than the parental silkworm silk fibers, and were as tough as native dragline spider silk fibers. The thread produced by the transgenic silkworms has a relative strength and flexibility of 80% to that of native spider silk. To ensure the silkworms were been genetically modified, a gene gave the transgenic silkworms red glowing eyes was also included.

PiggyBac transposon vectors mobilize via a "cut-and-paste" mechanism, reintegrating at other sites within the genome. PB transposase specifically recognizes PB inverted terminal repeats (ITRs) that flank the transposon, binding to these sequences and catalyzing the excision of the transposon. PB then integrates at TTAA sites throughout the genome, in a relatively random fashion. For the creation of transgenic animals, the transposase is supplied cotransfected with a plasmid containing donor transposon; subsequent integration within a coding region captures the elements necessary for gene expression. The findings were published ahead of print on January 3, 2012, in the Proceedings of the National Academy of Sciences (PNAS).

“These results demonstrate that silkworms can be engineered to manufacture composite silk fibers containing stably integrated spider silk protein sequences, which significantly improve the overall mechanical properties of the parental silkworm silk fibers,” concluded lead author Prof. Malcolm Fraser, PhD, and colleagues of the department of biomedical sciences.

Commercial production of spider silk is impractical, since spiders are too cannibalistic and territorial for farming. Researchers have experimented with producing the stronger material in other organisms, including bacteria, insects, mammals, and plants, but those proteins require mechanical spinning - a task the silkworms perform naturally. The stronger fiber could find application in sutures, where some natural silkworm silk is used, as well as wound dressings, artificial ligaments, cosmetics, parachute cords, and textiles.

Related Links:

University of Notre Dame




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.